Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
New CEO Szela cuts Aegerion staff again, pulls Juxtapid out of the EU
9 years ago
Merck is scouting sites for a new research hub in the Bay Area, plans new hires
9 years ago
AstraZeneca culls its neuroscience team, exits Kendall Square office
9 years ago
By the numbers: 2-year tally of Celgene's biotech partnership deals tops $3B in cash
9 years ago
AveXis wins the inside track at the FDA with gene therapy ‘breakthrough’
9 years ago
Synthorx lines up some big synthetic biology R&D goals after grabbing a $10M round
9 years ago
Beleaguered Zafgen crushed after FDA demands force it to dump lead drug
9 years ago
Valeant wins first round in $445M gamble on brodalumab approval
9 years ago
Merck KGaA blueprints a $115M 'collaboration campus' for Massachusetts
9 years ago
Merck-backed Quartet places biotech vet Gerhard Koenig at the helm
9 years ago
Celgene signs Jounce as its new biotech star in $2.6B ‘immuno-oncology 2.0’ pact
9 years ago
Celgene EVP Bagger gets a plum assignment on Trump team
9 years ago
Biotech vet Gould lands $55M startup round for a new Third Rock platform biotech
9 years ago
Novartis’ campaign to sweep biosimilar approvals hits a setback
9 years ago
Brainstorm’s rally fizzles after investors turn sour on questionable ALS data
9 years ago
Playing defense, Roche loses megafranchise gambit as Gazyva flunks head-to-head with Rituxan
9 years ago
With cash running low, little Evoke loses a crucial PhIII gamble
9 years ago
Which big biopharma companies put R&D as their top priority?
9 years ago
No minister: UK biotech community loses its dedicated government minister
9 years ago
Ziopharm craters on report of patient death in gene therapy study
9 years ago
AstraZeneca says it is pruning staff at MedImmune, its biologics R&D center
9 years ago
FDA review details suicides, cardio risks linked to Valeant’s $100M drug brodalumab
9 years ago
Q2 venture investing slows a tad, but the big money still flows into biotech
9 years ago
Financing
CAR-T player Juno grabs a PhII combo drug in $10M add-on deal
9 years ago
First page
Previous page
325
326
327
328
329
330
331
Next page
Last page